Home Featured Page 206

Featured

Latest

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

How Likely Are Bad Trips and Flashbacks from LSD?

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial...

PT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to...

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

1...205206207...300 Page 206 of 300

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

PT272 – Veterans Day 2021

How Likely Are Bad Trips and Flashbacks from LSD?

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial...

PT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to...

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

EDITOR PICKS

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY